These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28299790)

  • 1. TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.
    Choi M; Min YH; Pyo J; Lee CW; Jang CY; Kim JE
    Br J Pharmacol; 2017 Jun; 174(12):1810-1825. PubMed ID: 28299790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
    Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.
    Martinez R; Blasina A; Hallin JF; Hu W; Rymer I; Fan J; Hoffman RL; Murphy S; Marx M; Yanochko G; Trajkovic D; Dinh D; Timofeevski S; Zhu Z; Sun P; Lappin PB; Murray BW
    PLoS One; 2015; 10(9):e0138616. PubMed ID: 26398286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.
    Slee RB; Grimes BR; Bansal R; Gore J; Blackburn C; Brown L; Gasaway R; Jeong J; Victorino J; March KL; Colombo R; Herbert BS; Korc M
    Mol Cancer Ther; 2014 Feb; 13(2):307-315. PubMed ID: 24282275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.
    Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A
    Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
    Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
    Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
    Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase.
    Hiruma Y; Koch A; Dharadhar S; Joosten RP; Perrakis A
    Proteins; 2016 Dec; 84(12):1761-1766. PubMed ID: 27699881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
    Jemaà M; Galluzzi L; Kepp O; Senovilla L; Brands M; Boemer U; Koppitz M; Lienau P; Prechtl S; Schulze V; Siemeister G; Wengner AM; Mumberg D; Ziegelbauer K; Abrieu A; Castedo M; Vitale I; Kroemer G
    Cell Death Differ; 2013 Nov; 20(11):1532-45. PubMed ID: 23933817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
    Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
    Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
    Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
    J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
    Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K
    Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
    Wang S; Zhang M; Liang D; Sun W; Zhang C; Jiang M; Liu J; Li J; Li C; Yang X; Zhou X
    Eur J Med Chem; 2019 Aug; 175():247-268. PubMed ID: 31121430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
    J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TTK Inhibitors as a Targeted Therapy for
    Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
    Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
    Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
    Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
    Naud S; Westwood IM; Faisal A; Sheldrake P; Bavetsias V; Atrash B; Cheung KM; Liu M; Hayes A; Schmitt J; Wood A; Choi V; Boxall K; Mak G; Gurden M; Valenti M; de Haven Brandon A; Henley A; Baker R; McAndrew C; Matijssen B; Burke R; Hoelder S; Eccles SA; Raynaud FI; Linardopoulos S; van Montfort RL; Blagg J
    J Med Chem; 2013 Dec; 56(24):10045-65. PubMed ID: 24256217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
    M Serafim RA; da Silva Santiago A; Schwalm MP; Hu Z; Dos Reis CV; Takarada JE; Mezzomo P; Massirer KB; Kudolo M; Gerstenecker S; Chaikuad A; Zender L; Knapp S; Laufer S; Couñago RM; Gehringer M
    J Med Chem; 2022 Feb; 65(4):3173-3192. PubMed ID: 35167750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.